Target Information

Target General Infomation
Target ID
T09092
Former ID
TTDR00138
Target Name
Interleukin-10
Gene Name
IL10
Synonyms
CSIF; Cytokine synthesis inhibitory factor; IL-10; IL10
Target Type
Clinical Trial
Disease Endometriosis [ICD9: 617; ICD10: N80]
Inflammatory bowel disease; Psoriasis; Rheumatoid arthritis [ICD9: 555, 556, 696, 710-719, 714; ICD10: K50, K51, L40, M00-M25, M05-M06]
Solid tumours [ICD9: 140-199, 210-229; ICD10: C00-D48]
Scar tissue [ICD10: L00-L99]
Function
Inhibits the synthesis of a number of cytokines, including IFN-gamma, IL-2, IL-3, TNF and GM-CSF produced by activated macrophages and by helper T-cells.
BioChemical Class
Cytokine: interleukin
UniProt ID
P22301
Sequence
MHSSALLCCLVLLTGVRASPGQGTQSENSCTHFPGNLPNMLRDLRDAFSRVKTFFQMKDQ
LDNLLLKESLLEDFKGYLGCQALSEMIQFYLEEVMPQAENQDPDIKAHVNSLGENLKTLR
LRLRRCHRFLPCENKSKAVEQVKNAFNKLQEKGIYKAMSEFDIFINYIEAYMTMKIRN
Drugs and Mode of Action
Drug(s) F-8-IL-10 fusion protein Drug Info Phase 2 Endometriosis [524961]
Ilodecakin Drug Info Phase 2 Scar tissue [522798]
AM0010 Drug Info Phase 1 Solid tumours [524564]
Modulator AM0010 Drug Info [550272]
F-8-IL-10 fusion protein Drug Info [530407]
Ilodecakin Drug Info [527700]
Activator Ankinara Drug Info [536223]
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM)
TEP EXP Info
Pathways
KEGG Pathway Cytokine-cytokine receptor interaction
FoxO signaling pathway
Jak-STAT signaling pathway
T cell receptor signaling pathway
Intestinal immune network for IgA production
Pertussis
Leishmaniasis
Chagas disease (American trypanosomiasis)
African trypanosomiasis
Malaria
Toxoplasmosis
Amoebiasis
Staphylococcus aureus infection
Tuberculosis
Epstein-Barr virus infection
Asthma
Autoimmune thyroid disease
Inflammatory bowel disease (IBD)
Systemic lupus erythematosus
Allograft rejection
NetPath Pathway TCR Signaling Pathway
BCR Signaling Pathway
IL2 Signaling Pathway
IL4 Signaling Pathway
PANTHER Pathway Interleukin signaling pathway
Pathway Interaction Database Regulation of nuclear SMAD2/3 signaling
IL4-mediated signaling events
AP-1 transcription factor network
WikiPathways SIDS Susceptibility Pathways
Cytokines and Inflammatory Response
Allograft Rejection
References
Ref 522798ClinicalTrials.gov (NCT00984646) Investigation Into the Scar Reduction Potential of Prevascar (Interleukin-10). U.S. National Institutes of Health.
Ref 524564ClinicalTrials.gov (NCT02009449) A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
Ref 524961ClinicalTrials.gov (NCT02270632) A Randomized, Placebo-controlled Phase II Clinical Trial to Evaluate the Safety and Efficacy of F8IL10 Dekavil) in Patients With Active RA Receiving MTX. U.S. National Institutes of Health.
Ref 527700Ilodecakin. Schering-Plough Corp. IDrugs. 1999 Oct;2(10):1045-58.
Ref 530407Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis. Arthritis Res Ther. 2009;11(5):R142.
Ref 536223Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
Ref 550272Clinical pipeline report, company report or official report of ARMO BioSciences.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.